ANZCTR - Registration

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers

Trial registered on ANZCTR

Registration number

ACTRN12616001530415p

Ethics application status

Not yet submitted

Date submitted

1/11/2016

Date registered

7/11/2016

Date last updated

8/12/2024

Date data sharing statement initially provided

8/12/2024

Type of registration

Prospectively registered

Titles & IDs

Public title

The effectiveness of Transcranial Electro Stimulator Alternative - Hank Beckhoff (TESA-HB) in reducing the symptoms of Mild to Moderate Anxiety Episodes

Scientific title

A controlled randomised study of TESA-HB for reducing the symptoms of Mild to Moderate Anxiety Episodes.

Secondary ID [1]

Nil

Universal Trial Number (UTN)

U1111-1188-0136

Trial acronym

TESAAT

Linked study record

Health condition

Health condition(s) or problem(s) studied:

Anxiety

Condition category

Condition code

Mental Health

Anxiety

Mental Health

Depression

Intervention/exposure

Study type

Interventional

Description of intervention(s) / exposure

The participant will attend the NZCIH clinic and complete the following in the order listed below on Day 1. The participant will be given the opportunity to ask questions as needed.
Informed Consent Form (signature required)
1. Hamilton Anxiety Rating Scale (HAM-A)
2. The Psychological General Well-Being Index (PGWB-S)-1
3. Hamilton Depression Rating Scale (HAM-D21)
4. Brief History Record
5. Medication Usage Log
6. Sleep Questionnaire

The participant will then undertake a one hour clinical assessment with the Research Clinical Psychologist whereby all assessment tools will be evaluated and the Clinical Psychologist determines the participant’s suitability for enrollment.

Treatment Days: 1-4 and 6-9

Within seven (7) days of enrolment participants will attend the clinic for treatment each day for ten (10) days (5 days on, 2 days off, 5 days on) for 50mins each session. Treatments will be conducted at the same time of day, throughout the Treatment Period. This is the same for all two Treatment Arms - device types: 15mA and placebo.

The TESA-HB is a Cranial Electrotherapy Stimulator (CES) device manufactured by Annecto Ltd. This device delivers a micro-current with a proprietary waveform for the treatment of anxiety, depression, and insomnia.

The TESA-HB Device delivers a modified bipolar high frequency (65-100kHz) low milliamp (15 mA) alternating current (AC) signal monopolar and bipolar modulated at 76-79Hz. During process of bipolar modulation polarity of waveform will be changed every 7 minutes.

The device delivers a current to electrodes that are placed sagitally on the participant’s skin behind each ear over the mastoid area, on neck and on the forehead.

Participants who do not complete, or are unable to complete, their entire two weeks of therapy, or who miss more than 2 treatment days will not be included in the per-protocol (PP) analysis. These participants will continue to be followed in the study, but will be classified in the intent-to-treat (ITT) group.

Intervention code [1]

Treatment: Devices

Comparator / control treatment

All participants will be randomised to one of the two different arms, 50 participants in each group:
1. Treatment Arm A = 15mA TESA-HB Device
2. Treatment Arm B = Placebo Device
The front display of the arm B device will be absolutely identical to the front display of the arm A device and shows a digital read out of the treatment time. In contrast to the devices for arm A, devices for arm B will not deliver any current to participants. For both groups electrodes are applied to the skin surface: one to the forehead, one to neck and one behind each ear on the mastoid area. As there is no sensation by the electrodes the double blind method will not be compromised.

Control group

Placebo

Outcomes

Primary outcome [1]

Change in the total score on the Hamilton Anxiety Rating Scale (HAM-A)

Timepoint [1]

Baseline, Treatment days 5 and 10 and 12 weeks post last treatment session.

Secondary outcome [1]

Change in the total score on the Hamilton Depression Rating Scale (HAM-D)

Timepoint [1]

Baseline, treatment Day 10 and 12 weeks post last treatment session.

Secondary outcome [2]

Change in total score on the Psychological General Well-Being Scale (PGWB-S)-1

Timepoint [2]

Baseline, Treatment Day 5 and 10 and 8 and 12 weeks post last treatment session,

Secondary outcome [3]

Change in hours of sleep assessed by a study-designed sleep questionnaire

Timepoint [3]

Baseline, treatment days 1 - 10 and 2, 4, 8 and 12 weeks post last treatment.

Secondary outcome [4]

Change in quality of sleep assessed by a study-designed questionnaire.

Timepoint [4]

Baseline, treatment days 1 - 10 and 2, 4, 8 and 12 weeks post last treatment.

Eligibility

Key inclusion criteria

Diagnosed with a level of anxiety estimated from the Hamilton A (HAM-A) Rating Scale which categorises mild to moderate (18-24), or moderate to severe (25-30).

Minimum age

18 Years

Maximum age

65 Years

Sex

Both males and females

Can healthy volunteers participate?

Key exclusion criteria

Pregnancy, taking prescription or natural antidepressants or psychotropic medications, sensitivity to electrodes and/or their conductive gels or adhesives, break in skin integrity at the areas of electrode placement, currently taking immune suppressing drugs or suspected use of narcotics, presence of any implanted electronic device, (cardiac stimulator or Pacemaker), history of brain injury (including seizures, epilepsy, stroke, tumour of central nervous system, or hydrocephalus), history of heart attacks, congestive heart failure, or uncontrolled hypertension, history of schizophrenia or manic depressive syndrome.

Study design

Purpose of the study

Treatment

Allocation to intervention

Randomised controlled trial

Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)

On enrolment in the study a participant’s gender and HAM-A rating will be used as stratification variables for randomisation. A pre-computed randomisation table will be used to randomise. Since this is a double blinded study, the participant, the investigator, and other site personnel will not know which treatment will be received by the participant. All the TESA-HB devices will look identical, but each will be marked with a unique identification number. Only the Sponsor will know the unique numbers.

Methods used to generate the sequence in which subjects will be randomised (sequence generation)

A pre-computed randomisation table will be used to randomise.

Masking / blinding

Blinded (masking used)

Who is / are masked / blinded?

The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data

Intervention assignment

Parallel

Other design features

Phase

Not Applicable

Type of endpoint/s

Efficacy

Statistical methods / analysis

Recruitment of 100 participants was based on a trial “Effects of music therapy on pain and anxiety in patients undergoing bone marrow biopsy and aspiration” whereby they evaluated the effectiveness of music therapy interventions on pain and anxiety control for 100 patients.

The HAM-A is scored independently based on a five-point, ratio scale. A rating of 0 indicates that the feeling is not present in the patient. A rating of 1 indicates mild prevalence of the feeling in the patient. A rating of 2 indicates moderate prevalence of the feeling in the patient. A rating of 3 indicates severe prevalence of the feeling in the patient. A rating of 4 indicates a very severe prevalence of the feeling in the patient. The Clinical Psychologist proceeds through the fourteen items, evaluating each criterion independently in form of the five-point scale described above. A total of the composite score based upon the summation of each of the 14 individually rated items will be completed. This calculation will yield a comprehensive score in the range of 0 to 56. A score of 17 or less indicates mild anxiety severity. A score from 18 to 24 indicates mild to moderate anxiety severity. Lastly, a score of 25 to 30 indicates a moderate to severe anxiety severity.

The Psychological General Well-being Index (PGWB-S) twenty-two items of the questionnaire will be analysed in a linear multiple regression model. A score transformation will be applied to convert the lowest and highest possible scores to 0 (worst possible level of well-being) and 110 (maximum level of well being), respectively.

The HAM-D form lists 21 items, the scoring is based on the first 17. Eight items are scored on a 5-point scale, ranging from 0 = not present to 4 = severe. Nine are scored from 0-2. The sum of the scores from the first 17 items will apply within the following: 0-7 = Normal, 8-13 = Mild Depression, 14-18 = Moderate Depression, 19-22 = Severe Depression, = 23 = Very Severe Depression.

Recruitment

Recruitment status

Withdrawn

Reason for early stopping/withdrawal

Lack of funding/staff/facilities

Date of first participant enrolment

Anticipated

6/11/2017

Actual

Date of last participant enrolment

Anticipated

4/12/2017

Actual

Date of last data collection

Anticipated

22/01/2018

Actual

Sample size

Target

100

Accrual to date

Final

Recruitment outside Australia

Country [1]

New Zealand

State/province [1]

Bay of Plenty

Funding & Sponsors

Funding source category [1]

Commercial sector/Industry

Name [1]

Annecto LLC

Address [1]

252 West Swamp Road
Doylestown
Pennsylvania 18901
USA

Country [1]

United States of America

Primary sponsor type

Commercial sector/Industry

Name

New Zealand Centre of Integrated Health

Address

Suite 6, Promed House
71 10th Avenue
Tauranga 3110

Country

New Zealand

Secondary sponsor category [1]

Individual

Name [1]

Dr Anna Rolleston

Address [1]

Cardiac Clinic
103 Third Ave
Tauranga 3110

Country [1]

New Zealand

Ethics approval

Ethics application status

Not yet submitted

Ethics committee name [1]

Health and Disability Ethics Committee

Ethics committee address [1]

Ministry of Health
Ethics Department
Freyberg Building
Reception - Ground Floor
20 Aitken Street
Wellington 6011

Ethics committee country [1]

New Zealand

Date submitted for ethics approval [1]

14/11/2016

Approval date [1]

Ethics approval number [1]

Summary

Brief summary

Anxiety is a major health problem worldwide and the lifetime prevalence in New Zealand is approximately 25%. The key features of anxiety are uncontrollable, persistent and excessive nervousness and worry across specific or all settings, and relate to the anticipation of a future threat. The recent NZ Mental Health Survey, September 2016, showed mental disorder is common in New Zealand: 46.6% of the population are predicted to meet criteria for a disorder at some time in their lives, with 39.5% having already done so and 20.7% having a disorder in the past 12 months. 
According to the Health Loss in New Zealand study, anxiety and depressive disorders are the second leading cause of health loss for New Zealanders, accounting for 5.3% of all health loss, behind only coronary heart disease (9.3%). Anxiety has detrimental effects, some lasting many years and left untreated, anxiety limits an individual’s daily functioning, often avoiding many aspects of life in an attempt to cope with, and relieve, the anxiety. Several medical devices using microcurrent levels of electrical stimulation have been approved for use in the area of anxiety, however the most effective waveform, current and application process, has not been determined.
The TESA-HB Device ANNECTO LLC is a transcranial electronic stimulation device delivers a modified bipolar high frequency low milliamp (15mA) alternating current (AC) modulated at 76-79Hz applied cranially through four external electrodes and is intended for the long-term reduction of pain. It is hypothesised that the TESA-HB Technology could also help to decrease depression, anxiety, and insomnia.

Researchers have noted that transcranial electronic stimulation applied within quasi resonance, resulted in stimulation and activation of the antinociceptive system with its endorphinergic and serotoninergic mechanisms.

The purpose of this work is to determine the effectiveness of the TESA-HB in reducing the symptoms of anxiety in people with mild to moderate episodes.  The specific aims of the project are to determine the effect of 10 days of TESA-HB treatment on psychological general well-being, quality of sleep, quantity of sleep, quality of life, and anxiety score.
100 participants (18-65 years) will be recruited from the Tauranga area.  The criteria for inclusion is a level of anxiety estimated from the Hamilton A (HAM-A) Rating Scale which categorises mild to moderate (18-24), or moderate to severe (25-30).
The participant will attend the NZCIH clinic and complete questionnaires on Day 1. The participant will be given the opportunity to ask questions as needed. The participant will then undertake a one hour clinical assessment with the Research Clinical Psychologist whereby all assessment tools will be evaluated and the Clinical Psychologist determines the participant’s suitability for enrolment.

Within seven (7) days of enrolment participants will attend the clinic for treatment each day for ten (10) days (5 days on, 2 days off, 5 days on) for 50mins each session. Treatments will be conducted at the same time of day, throughout the Treatment Period. This is the same for all two Treatment Arms - device types: 15mA and placebo.  

The device delivers a current to electrodes that are placed sagitally on the participant’s skin behind each ear over the mastoid area, on neck and on the forehead. 

Participants will return to the Clinic for follow up evaluations at 2 weeks, 4 weeks, 8 weeks and 12 weeks after completion of the last treatment.

Trial website

Trial related presentations / publications

Public notes

Contacts

Principal investigator

Name

Dr Anna Goodwin

Address

New Zealand Centre of Integrated Health
Suite 6, Promed House
71 10th Avenue
Tauranga 3110

Country

New Zealand

Phone

+64275203112

Fax

+6475795110

annag@braemarhospital.co.nz

Contact person for public queries

Name

Desiree De Spong

Address

New Zealand Centre of Integrated Health
Suite 6, Promed House
71 10th Avenue
Tauranga 3110

Country

New Zealand

Phone

+64275443424

Fax

+6475795510

desiree@aetiology.co.nz

Contact person for scientific queries

Name

Anna Rolleston

Address

Cardiac Clinic
103 Third Ave
Tauranga 3110

Country

New Zealand

Phone

+6475786624

Fax

anna@thecardiacclinic.co.nz

Data sharing statement

Will individual participant data (IPD) for this trial be available (including data dictionaries)?

No/undecided IPD sharing reason/comment

What supporting documents are/will be available?

No Supporting Document Provided

Results publications and other study-related documents

Documents added manually

No documents have been uploaded by study researchers.

Documents added automatically

No additional documents have been identified.

Trial Review

Registering a new trial?

Documents added manually

Documents added automatically